VRAX
VRAX
NASDAQ · Health Care

Virax Biolabs Group Ltd

$2.31
-0.08 (-3.37%)
As of Sep 28, 10:49 PM ET ·
Financial Highlights (FY 2026)
Revenue
42.1K
Net Income
-17,062,000
Gross Margin
61.9%
Profit Margin
-40,448.9%
Rev Growth
+13.2%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.9% 61.9% 64.6% 64.6%
Operating Margin -51,527.6% -46,374.9% 17.5% 18.8%
Profit Margin -40,448.9% -38,426.4% 12.3% 15.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 42.1K 37.2K 538.6K 459.7K
Gross Profit 26.1K 23.0K 347.9K 296.9K
Operating Income -21,708,586 -17,257,951 94.4K 86.3K
Net Income -17,062,000 -13,563,996 66.4K 71.8K
Gross Margin 61.9% 61.9% 64.6% 64.6%
Operating Margin -51,527.6% -46,374.9% 17.5% 18.8%
Profit Margin -40,448.9% -38,426.4% 12.3% 15.6%
Rev Growth +13.2% +13.2% -4.1% +16.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 86.8K 86.8K 385.3K 374.1K
Total Equity 1.59M 1.59M 916.7K 903.3K
D/E Ratio 0.05 0.05 0.42 0.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -20,244,171 -16,987,865 122.1K 91.8K
Free Cash Flow — — 82.7K 52.1K